Authors' Reply: Further Considerations on the Clinical Evaluation of Sotagliflozin in Type 1 Diabetes with CKD
Bibliographic record
Abstract
We appreciate the opportunity to respond to the Letter to the Editor by Wang et al.1 on our article published in JASN on the efficacy and safety of sotagliflozin in patients with type 1 diabetes and CKD.2 People with type 1 diabetes continue to have high burden of CKD and kidney failure, with a conspicuous absence of new therapies beyond glycemic control and renin-angiotensin system blockade. We therefore evaluated the safety and efficacy of the sodium-glucose cotransporter 1 (SGLT1) and 2 inhibitor sotagliflozin in a post hoc analysis using participant-level data from the inTandem 1, 2, and 3 trials of sotagliflozin in people with type 1 diabetes. While we agree with Wang et al. that factors such as smoking history, diet, and exercise are predictors of cardiorenal outcomes in patients with type 1 diabetes, as reflected by their incorporation into type 1 diabetes specific risk prediction models,3 these variables were unavailable in the inTandem 1, 2, and 3 trials and, therefore, unable to be incorporated into our analyses. Our colleagues' points on the importance of prospective and longitudinal analyses of kidney function when evaluating the efficacy of therapeutics on kidney outcomes are well taken. We would like to re-emphasize that inTandem 1, 2, and 3 were trials with glycemic end points without enrichment for cardiovascular and kidney end points and with relatively short periods of follow-up. Therefore, we did not focus on more traditional kidney end points including longitudinal changes in eGFR modeled as defined percentage changes over follow-up or as annualized eGFR slope. However, acute effects of SGLT inhibition on eGFR, as observed in our analyses, have been highly associated with longer-term kidney protection, possibly through activation of glomerular hemodynamic mechanisms.4,5 Dedicated clinical trials in patients at high risk of cardiorenal complications are clearly warranted to better understand both clinical benefits and safety of SGLT inhibition in patients with type 1 diabetes and CKD. The ongoing SodiUm Glucose co-trAnspoRt inhibitioN diabeteS And kidney function Loss in Type 1 diabetes trial (SUGARNSALT, NCT06217302) will evaluate the efficacy and safety of sotagliflozin versus placebo in patients with type 1 diabetes, eGFR 20–60 ml/min per 1.73 m2, and albuminuria. As a multicenter trial with well-defined participant selection criteria, collection of granular longitudinal data on kidney function, cardiovascular outcomes, the implementation and assessment of a robust diabetic ketoacidosis mitigation protocol, as well as a predefined economic analysis, we are confident that SUGARNSALT will be a definitive evaluation of SGLT inhibition in patients with type 1 diabetes and moderate-to-severe diabetic kidney disease, particularly with respect to slowing kidney disease progression.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.009 | 0.058 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.002 | 0.003 |
| Scholarly communication | 0.003 | 0.005 |
| Open science | 0.004 | 0.002 |
| Research integrity | 0.034 | 0.044 |
| Insufficient payload (model declined to judge) | 0.006 | 0.006 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".